Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisPatient reported outcomes in rheumatoid arthritis clinical trialsEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesAdvances in the treatment of rheumatoid arthritis.Subcutaneous abatacept for the treatment of rheumatoid arthritis.New pharmacological strategies in rheumatic diseasesComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.Comparative effectiveness research with administrative health data in rheumatoid arthritis.Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and CanadaA phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoiRheumatoid arthritis quality measures and radiographic progression.Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial FibroblastsBiologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialReductions in disease activity in the AMPLE trial: clinical response by baseline disease durationUse of biologics in a patient with rheumatoid arthritis refractory to methotrexate.Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.New methods for determining comparative effectiveness in rheumatoid arthritisValue of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing.Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisEmerging therapies for rheumatoid arthritis.Abatacept: a review of its use in the management of rheumatoid arthritis.Update on the use of abatacept for the treatment of rheumatoid arthritis.Current immunotherapy in rheumatoid arthritis.Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
P2860
Q24185797-3B785CCF-6060-4AC8-9E9D-4D591A81A303Q26852960-89D31CD5-31E2-492D-9D78-A6E64028F3C3Q26859134-2AA490EB-05DF-4319-9FD9-B7695B43DF26Q26991673-D82CA6AD-5392-45F4-85E1-C3958E1DEF6EQ27691822-EC20885C-E857-47F0-8E80-1299939035E4Q27692117-314033FD-F29C-4C58-BC3F-D76E348DA1B0Q28073763-DBDA6858-2417-4275-8E28-13727F413D5AQ28547851-57FF86D3-199A-4BB9-A97B-1C4AD21144B7Q30234528-A937E1A2-B3F4-4B07-A681-A4C52BF4D53DQ30235341-34436789-8AD0-46B3-A373-FEDAE8FFE941Q30863740-CA1F9B84-FD18-4E86-A226-CFAB670C6AB2Q31077662-22ADD521-4722-4929-9457-416086658B01Q33841358-37AFA1AA-ABF3-47B9-9E7F-20DEB19DE135Q33921820-5DF4686F-B07B-41BB-86C4-7BF13EA94187Q33953283-2A1CA57B-8514-4EB5-A4FB-71B6128EEC32Q34409073-F8005C8D-B6A7-4BFD-91F4-A1E14A337B6EQ34500921-48668D5A-F987-44DD-9145-5276B1B34161Q34656204-97AE46E8-2E4B-46A0-97F0-8648C9C6B9A4Q34752154-0D2D5D1F-A348-4433-A6B2-445A9FD3D36DQ35982598-1AC4A068-566D-4764-A272-BA1D52F7343BQ36195284-44973072-8558-4862-B5BA-F36B52ABA1C3Q36761916-61B6CF97-DD63-4661-85FA-71CA2B0A25A9Q36819289-62615317-56FF-4C51-8A19-F2245361E3CBQ36923376-FF94BB53-0A46-45C1-91A1-EAEF74E6590FQ36968747-14B7D31F-D03C-4925-9A5E-7F0CFDE2909CQ37274242-1099A843-F415-425B-9474-5CE061139167Q37282494-DD1CD753-D9C8-42CB-A7D7-52892F0468E5Q37330765-0847DA8B-8F00-4299-A6EA-3041EBD18901Q37391811-9A08157D-60D6-4DE6-960E-DC9A2F6B81B6Q37465523-8962CCA9-26A9-4331-A8ED-A5A3E6F5A04EQ37587412-1AF98951-6532-4389-9247-D26A8F19511AQ37600477-38DCCB97-5A41-4AC3-A26A-DD089C796503Q37690095-60FB9E88-40E8-4621-A186-740AFABC77C5Q38091288-87D5AC31-FAA8-45EF-A811-78DAB8096B85Q38110963-4A44763A-EC39-4880-91B4-FE74DA22563EQ38116472-2BB8E264-5B63-4731-8143-4BFC5F952F62Q38125240-F96ED705-5EF4-4DC9-99F3-55BC0FB3E54DQ38133655-50C4852D-D10A-4005-B946-BA2BD47EB53AQ38170177-A665B392-331D-41F0-9B14-E359F1A32F55Q38176549-719110FE-7A52-4804-BEA0-66D1B7FC8FA7
P2860
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Head-to-head comparison of sub ...... prospective, randomized study.
@ast
Head-to-head comparison of sub ...... prospective, randomized study.
@en
type
label
Head-to-head comparison of sub ...... prospective, randomized study.
@ast
Head-to-head comparison of sub ...... prospective, randomized study.
@en
prefLabel
Head-to-head comparison of sub ...... prospective, randomized study.
@ast
Head-to-head comparison of sub ...... prospective, randomized study.
@en
P2093
P2860
P356
P1476
Head-to-head comparison of sub ...... prospective, randomized study.
@en
P2093
Cathy Zhao
Gustavo Citera
Michael E Weinblatt
Michael Maldonado
Michael Schiff
Robert Valente
Roy Fleischmann
P2860
P356
10.1002/ART.37711
P577
2013-01-01T00:00:00Z